Fox Run Management’s Myriad Genetics MYGN Stock Holding History

Fox Run Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-29,918	Closed	-$216K	–	1128
2025 Q3	$216K	Buy	+29,918	New	+$178K	0.03%	781
2024 Q4	–	Sell	-53,141	Closed	-$1.46M	–	1068
2024 Q3	$1.46M	Buy	+53,141	New	+$1.44M	0.32%	36
2024 Q2	–	Sell	-17,120	Closed	-$365K	–	967
2024 Q1	$365K	Buy	+17,120	New	+$368K	0.08%	470
2019 Q1	–	Sell	-25,703	Closed	-$747K	–	617
2018 Q4	$747K	Buy	25,703 +18,027	+235%	+$649K	0.4%	30
2018 Q3	$353K	Sell	7,676 -16,555	-68%	-$736K	0.15%	296
2018 Q2	$906K	Buy	+24,231	New	+$818K	0.29%	50
2017 Q2	–	Sell	-18,268	Closed	-$351K	–	756
2017 Q1	$351K	Buy	18,268 +1,168	+7%	+$20.7K	0.14%	312
2016 Q4	$285K	Buy	+17,100	New	+$309K	0.15%	316
2016 Q3	–	Sell	-12,800	Closed	-$392K	–	614
2016 Q2	$392K	Sell	12,800 -6,700	-34%	-$233K	0.19%	191
2016 Q1	$730K	Buy	+19,500	New	+$735K	0.49%	24

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCM

Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fox Run Management's MYGN Position: Q4 2025 in Review

Fox Run Management sold out of Myriad Genetics (MYGN) in Q4 2025, closing a stake of 29,918 shares — an estimated $216K sold.

Fox Run Management first reported a position in MYGN in Q1 2016 and held it in 10 quarters. The position peaked at $1.46M in Q3 2024. 221 funds tracked by Wall St. Rank hold MYGN as of Q4 2025.

Fox Run Management reported no remaining Myriad Genetics position as of Q4 2025 after selling out during the quarter.
Fox Run Management sold 29,918 Myriad Genetics shares in Q4 2025, an estimated $216K.
Fox Run Management first reported a position in Myriad Genetics in Q1 2016 and held it in 10 quarters.
Fox Run Management's Myriad Genetics position peaked at $1.46M in Q3 2024.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2025.

Based on Fox Run Management's 13F filing for Q4 2025, filed 11 Feb 2026.